Recall of Anemia Drug Omontys Rings Alarm Over Biosimilars

          Recall of Anemia Drug Omontys Rings Alarm Over Biosimilars

PR Newswire

ATLANTA, Feb. 27, 2013

ATLANTA, Feb. 27, 2013 /PRNewswire-USNewswire/ --Makers of innovative
biologics have legitimate reason to sound alarms about automatic substitution
of biosimilars that have not proven their interchangeability – and it's not
just because of the potential impact to their bottom line. That point was
driven home by the recent recall of Affymax Inc. and Takeda Pharmaceutical Co.
Ltd.'s anemia drug Omontys (peginesatide), according to BioWorld.


Though Omontys is not a biosimilar, the unexpected postmarketing reports of
serious hypersensitivity reactions (three patient deaths) linked to the
erythropoiesis-stimulating agent (ESA) served as a reminder of the variability
of biologics, their sensitivity to minute manufacturing changes and the
difficulty of catching a rare safety signal in the full-blown biologic
development process – let alone an abbreviated biosimilar path, as noted in a
blog post by BioWorld Washington Editor Mari Serebrov

This should give the FDA pause about its approach to biosimilar approval.
Because of the variability of biologics, biotechs and patient advocacy groups
have urged the agency to require safety data for biosimilars. While the FDA
maintains that patient safety is its primary concern with any drug, it insists
that since the reference biologic has demonstrated safety and efficacy, all a
biosimilar must do is demonstrate similarity to the reference drug. The goal
is not to require redundant clinical trials that would be expensive,
unnecessary and unethical.

Neither the FDA nor most biotechs want the biosimilar path to fail. But they
understand the complexities of making biologics, and they know that one
disaster now could doom or indefinitely delay the new approval path.

Unfortunately, people unfamiliar with the differences between biologics and
small molecule drugs, which are far less complex than biologics, too often
equate biosimilars with generics. Since generics are unquestionably accepted
as equivalent to small molecule reference drugs, they can be substituted
automatically for the brand drug at the pharmacy. Yet even generics have had
equivalency problems.

Editor's note: This is an excerpt from a BioWorld Perspectives Blog post. Read
the complete post:

BioWorld ‑ the industry's most trusted news service focused on the development
of biologics for more than two decades ‑ has identified and profiled 139 key
biosimilar developers with >276 biosimilars in their pipelines, according to
The Biosimilars Game: A Scorecard for Opportunities, Threats and Critical
Strategies, a new report by BioWorld Data. Call for details (800) 477-6307.

Contact: Lynn Yoffee


Press spacebar to pause and continue. Press esc to stop.